Composition
Remogliflozin Etabonate Tablets
Interested in this product?
Contact us for export pricing, bulk orders, and regulatory documentation.
Request QuoteProduct Overview
Remoberg contains Remogliflozin, an SGLT2 inhibitor that promotes urinary glucose excretion to lower blood glucose with associated weight loss benefits.
Indication
Type 2 diabetes mellitus as monotherapy or add-on therapy to Metformin.
Packaging
10 x 10 Alu-Alu strip pack
Storage
Store below 25°C, protected from light.
Export Ready
Available for export with full regulatory documentation, COA, and dossier support for international registration.
Disclaimer: This product information is intended for healthcare professionals and authorized distributors only. It is not intended as medical advice. Please refer to the full prescribing information for complete details. Regulatory approvals may vary by country.